Sera Prognostics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SERA research report →
Range $6 – $6
Price Chart
About the company
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present.
- CEO
- Zhenya Lindgardt
- IPO
- 2021
- Employees
- 72
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on SERA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $70.23M
- P/E
- -2.70
- PEG
- -0.21
- P/S
- 731.58
- P/B
- 1.75
- EV/EBITDA
- -2.13
- Div Yield
- 0.00%
- Gross Margin
- -103.13%
- Op Margin
- -38755.21%
- Net Margin
- -34866.67%
- ROE
- -52.54%
- ROIC
- -66.78%
Latest fiscal year · YoY change
- Revenue
- $81.00K+5.2%
- Gross Profit
- $-83,000-1560.0%
- Op Income
- $-36,504,000
- Net Income
- $-31,928,000+2.9%
- EPS
- $-0.67+32.3%
- OCF Growth
- -80.6%
- FCF Growth
- -72.3%
- 52W High
- $3.85
- 52W Low
- $1.56
- 50D MA
- $2.03
- 200D MA
- $2.05
- Beta
- 1.14
- RSI (14)
- 37
- Avg Volume
- 27.84K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sera said Q3 marked a real commercial inflection, with PreTRM volumes up sharply, reimbursement expanding in Illinois and Florida, and management targeting further growth into 2027.· November 4, 2026
- Test volume rose 54% sequentially in Q3 and was almost fivefold higher than Q1 2026; ordering physicians and accounts also accelerated.
- Medicaid coverage expanded to Illinois and Florida, bringing roughly 7 million covered lives and about 140,000 annual Medicaid births into reach.
- Management said Florida pricing is around $450 and expects Medicaid reimbursement in most states to remain tied to Medicare-based fee schedules.
- The company has 4 active commercial pilot programs, including 2 with major national health plans, and expects a PRIME health economics publication in Q4.
- Cash was $72.8 million at quarter-end, and management said it believes cash is sufficient to fund operations into fiscal 2029.
Sera did not give full quarterly revenue or EPS figures on the call. The company said total PreTRM test volumes increased almost fivefold from the first quarter of 2026, and Lee Anderson said Q3 test volume increased 54% sequentially from Q2. Management said operating expenses declined 11% sequentially, while ASPs fell in Q3 because a larger share of patients came from low- or non-reimbursed classes. The company ended the quarter with $72.8 million in cash and cash equivalents. Looking ahead, management expects ASPs to begin reversing in fiscal 2027 as Florida and Illinois Medicaid mix grows and commercial pilot volume increases; it also expects flat or lower operating expenses in 2027 while significantly expanding the commercial team. No formal next-quarter or full-year revenue/EPS guidance was provided.
The CEO framed Sera as moving from evidence generation into commercialization, saying the company is trying to make PreTRM a foundational part of prenatal care and a new category in maternal health. She emphasized that Illinois and Florida coverage validate a repeatable reimbursement playbook, that the company is on track for CE Mark submission for PreTRM Global in 2027, and that the business is focused on scalable growth, broader access, and capital discipline. Her tone was confident and constructive, but she repeatedly stressed that execution still matters and that the company is early in the commercialization curve.
The CFO highlighted the key financial bridge: volumes are rising quickly, but ASPs were pressured in Q3 because more tests came from low or non-reimbursed patient classes. He said the company recognized its first milestone payment under a subcontract award as other income, and that operating expenses fell 11% sequentially due to targeted cost-saving efforts, partly offset by incremental commercial investment in Illinois and Florida. He ended with $72.8 million in cash and said Sera believes it has enough liquidity to fund operations into fiscal 2029, while also expecting flat or down operating expenses in 2027 even as the commercial team grows.
Analysts focused on Florida reimbursement, potential restrictions, the reimbursement rate, and whether a major managed care relationship could lead to national coverage. Management said there are no restrictions for Florida Medicaid coverage, the rate is in the low $400s and was уточ explicitly as $450, and the company believes it can manage that cost structure at scale. On the managed-care question, management said it absolutely believes the discussions could lead to national coverage, but timing will be step-by-step and likely requires pilot data and payer review cycles first.
The bull case from the call is that Sera is finally showing tangible commercial traction: more physicians, more accounts, and sharply higher test volumes after the PRIME study and new commercial leadership. Reimbursement is broadening in two large states, the company has multiple payer pilots underway, and management sounded increasingly confident that the evidence package can support broader coverage.
The main risks are execution and timing: management said it can take 12 to 18 months for physicians to move from awareness to high-volume standard-of-care adoption, and national coverage decisions may still depend on pilot readouts and payer review cycles. ASPs fell in Q3 because of mix, Florida pricing is only about $450, and the company is still early in building durable commercial scale despite the positive momentum.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.2%
- Shares Outstanding
- 38.80M
- Float Shares
- 28.02M
of shares held by institutions
47 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 5.50M | 0 |
| Whetstone Capital Advisors, LLC | 3.31M | 0 |
| Aberdeen Group PLC | 2.95M | ▲ 199.67K |
| Vivo Capital, LLC | 1.65M | 0 |
| Vanguard Capital Management LLC | 1.30M | 0 |
| Vanguard Group Inc | 1.24M | ▲ 22.26K |
| Geode Capital Management, LLC | 348.97K | 0 |
| Captrust Financial Advisors | 306.86K | ▼ 228.89K |
| Blackrock, Inc. | 223.37K | ▲ 2.00K |
| Vanguard Fiduciary Trust Co | 208.25K | ▲ 37.34K |
| Awm Investment Company, Inc. | 207.38K | 0 |
| State Street Corp | 124.79K | 0 |
Held by 33 ETFs
Biggest fund positions in SERA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 12, 26 | Inglis Tiffany Eul Davis | sell | 8,024 |
| Sep 10, 26 | Anderson Dyaarl Lee Jr. | sell | 1,800 |
| Sep 10, 26 | Lindgardt Zhenya | sell | 7,022 |
| Sep 10, 26 | Inglis Tiffany Eul Davis | sell | 486 |
| Sep 10, 26 | Jackson Benjamin | sell | 2,190 |
| Sep 8, 26 | Lindgardt Zhenya | sell | 20,139 |
| Aug 31, 26 | Aerts Austin | other | 0 |
| Aug 31, 26 | Gleason Scott | other | 169,624 |
| Aug 31, 26 | Gleason Scott | other | 117,924 |
| Aug 31, 26 | Gleason Scott | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SERA coverage
Recent articles, reports, and earnings notes.
No research on SERA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SERA report →Sera: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
Sera Prognostics, Inc. (SERA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Sera Prognostics (SERA) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 4
SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
prnewswire.com · Nov 4
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
prnewswire.com · Oct 21
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
prnewswire.com · Aug 25
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
prnewswire.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.